Pórszász, RóbertHong, HyeJung2020-02-242020-02-242019-05-31http://hdl.handle.net/2437/281192The pharmacological treatment of inflammatory bowel disease (IBD) over the last two decades has transitioned from treatment with aminosalycilates, corticosteroids and immunomodulators to treatment with anti-tumor necrosis factor (anti-TNF) therapy. Nevertheless, anti-TNF therapy is discontinued in 20-30% of patients for primary non-response and in another 30-40% for losing response within one year of treatment. Pharmacokinetic (antidrug antibodies and/or low drug concentrations) or pharmacodynamic issues which is characterized by a non-TNF driven inflammation attribute undesirable therapeutic outcomes. The use of medications with different mechanisms of action is necessitated by the latter issues. Besides the biologics natalizumab, vedolizumab and ustekinumab have been investigated as treatment of IBD new non-anti-TNF therapies, including small molecule drugs against Janus kinase and sphingosine-1-phosphate receptors. New advanced biological medication that are in the later stages of development for the treatment of IBD and directed against immune targets other than TNF will be reviewed by this manuscript.39ennew biological treatmentinflammatory bowel diseaseDEENK Témalista::Orvostudomány::Farmakológia